COVID-19 Convalescent Plasma Therapy: Long-term Implications.
Hyunah YoonYi LiKeith S GoldfeldGia F CobbCaroline L Sturm-ReganatoLuis Ostrosky-ZeichnerDushyantha T JayaweeraJulie V PhilleyMahalia S DesruisseauxMarla J KellerJudith S HochmanLiise-Anne PirofskiMila Brum Ortigozanull nullPublished in: Open forum infectious diseases (2023)
CCP demonstrated no lasting effect on PASC symptoms or overall health in comparison to the placebo. This study underscores the significance of demographic factors, including sex, age, and timing of acute infection, in influencing symptom reporting 18 months after acute hypoxic COVID-19 hospitalization.
Keyphrases
- coronavirus disease
- sars cov
- healthcare
- public health
- liver failure
- mental health
- respiratory syndrome coronavirus
- emergency department
- health information
- stem cells
- clinical trial
- physical activity
- depressive symptoms
- aortic dissection
- intensive care unit
- patient reported
- phase iii
- risk assessment
- electronic health record